Sign In
Buy CWBR
$0.410
+0 (+0%)
At Close: Apr 22, 2025
CohBar Appoints Carol Nast to Its Board of Directors
09:00am, Monday, 16'th Aug 2021
MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar Shares Increased 25.58%: Why It Happened
06:09am, Thursday, 12'th Aug 2021
The shares of CohBar Inc (NASDAQ: CWBR) increased 25.58%. This is why it happened.
CWBR Stock Price Increases Over 75% Intraday: Why It Happened
03:40pm, Wednesday, 11'th Aug 2021
The stock price of CohBar Inc (NASDAQ: CWBR) increased by over 75% during intraday trading. This is why it happened.
CohBar's (CWBR) CEO Joe Sarret on Q2 2021 Results - Earnings Call Transcript
09:21pm, Tuesday, 10'th Aug 2021
CohBar's (CWBR) CEO Joe Sarret on Q2 2021 Results - Earnings Call Transcript
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
04:04pm, Tuesday, 10'th Aug 2021
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
04:02pm, Tuesday, 10'th Aug 2021
MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months
11:42am, Wednesday, 14'th Jul 2021
CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity. The process of data
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity
09:00am, Wednesday, 14'th Jul 2021
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
CohBar, Inc. (CWBR) CEO Joe Sarret on Q1 2021 Results - Earnings Call Transcript
11:07pm, Monday, 17'th May 2021
CohBar, Inc. (CWBR) CEO Joe Sarret on Q1 2021 Results - Earnings Call Transcript
CohBar Appoints Joseph J. Sarret, M.D.
08:30am, Tuesday, 27'th Apr 2021
Announces change to the Board of Director's Chair Announces change to the Board of Director's Chair
CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics
01:22pm, Friday, 23'rd Apr 2021
CohBar, Inc. is an interesting early-clinical-stage biotechnology company developing mitochondrial-based therapeutics for treating chronic and age-related diseases including nonalcoholic steatohepatit
New Strong Sell Stocks for April 22nd
10:31am, Thursday, 22'nd Apr 2021
CWBR, KL, MUX, NSANY, and PAA have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2021
CohBar, Inc. (CWBR) CEO Steve Engle on Q4 2020 Results - Earnings Call Transcript
10:21pm, Tuesday, 30'th Mar 2021
CohBar, Inc. (CWBR) CEO Steve Engle on Q4 2020 Results - Earnings Call Transcript
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
04:02pm, Tuesday, 30'th Mar 2021
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
09:00am, Monday, 29'th Mar 2021
MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte
